Client success story
Preclinical Biostatistics Analysis
Business Value: Strengthening Preclinical Assay Reliability for Confident Drug Assessment
Summary: Optimizing the Statistical Power of Electroshock Models
bPrescient worked with a clinical-stage biotechnology company to assess the statistical power of electroshock models and determine the best methods for eliminating noise and reducing the dimensionality of the data. These efforts allowed the company to confidently use the models to assess clinical candidates.
Challenge: Reducing Data Noise and Dimensionality for Assay Comparison
The company develops pre-clinical assays and models to assess therapeutics for medical disorders, and a key model is the use of electroshock in vivo to assess the anti-seizure effects of therapeutics. However the statistical power of the test to detect a significant response was unknown, and the amount of noise and high dimensionality of the data led to challenges in comparing data across assays.
Solution: bPrescient Experts Define Statistical Confidence and Data Reduction Strategies
bPrescient’s senior biostatistician worked with the company’s scientists to review the existing test data that was available, defined the statistical power of the test based on sample data, and produced confidence intervals for assays results. Subsequently, the consultant worked with the company’s scientists to identify the goals for data reduction needs and produced methods to reduce dimensionality and noise that enabled better cross-assay correlation measures.
Outcome: Improved Assay Precision for Preclinical Candidate Evaluation
The company received information on power calculations, confidence interval definitions, and noise and dimensionality reduction methods for their assays, allowing them to be used with confidence in a pre-clinical setting.
Let’s talk
Tell us about your toughest R&D challenge and let’s discuss how bPrescient can solve it.
